Publication Cover
Hemoglobin
international journal for hemoglobin research
Volume 41, 2017 - Issue 3
78
Views
1
CrossRef citations to date
0
Altmetric
Original Article

α+-Thalassemia Caused by an 811 bp Deletion in Individuals from Nanning, Guangxi: A Report of Two Cases

, , &
Pages 185-188 | Received 23 Mar 2017, Accepted 18 Jul 2017, Published online: 27 Sep 2017
 

Abstract

A novel 811 bp deletion was first identified in two families of Nanning City, Guangxi Zhuang Autonomous Region, People’s Republic of China (PRC). The molecular basis of this anomaly is a deletion from NG_000006.1: g.32945_33755, and is 20 bp upstream of the translation initiation codon of HBA2. From analyses of the blood indices of the two probands, the 811 bp deletion is an α+-thalassemia (α+-thal). This is the first report of this deletional thalassemia anywhere in the world.

Acknowledgments

The authors would like to thank Dr. Dev Sooranna, Imperial College London, London, UK for helping to edit the manuscript.

Disclosure statement

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.

Additional information

Funding

This study was funded by the Guangxi Science and Technology Department [Gui 14124004-1 and Gui 1598012-21], the Health Department of Guangxi Province [Z2014146] and the Natural Science Foundation of China [81260093; 81370670].

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.